دورية أكاديمية
Neuropsychiatric Consequences of COVID-19 Pandemic: A Synthetic Review from a Global Perspective.
| العنوان: | Neuropsychiatric Consequences of COVID-19 Pandemic: A Synthetic Review from a Global Perspective. |
|---|---|
| المؤلفون: | Pandi-Perumal SR; Somnogen Canada Inc., College Street, Toronto, Canada.; Saveetha Medical College and Hospitals, Saveetha Institute of Medical and Technical Sciences, Saveetha University, Chennai, India., Zaki NFW; Sleep research unit, Department of Psychiatry, Faculty of Medicine, Mansoura University, Egypt.; Department of Psychiatry, North Area Armed Forces Hospital (NAAFH) KSA, Saudi Arabia., Qasim M; Department of Rehabilitation Medicine, North Area -Armed Forces Hospital (NAAFH)-KSA, Saudi Arabia., Elsayed Morsy N; Department of Chest Medicine, Faculty of Medicine, Mansoura University, Egypt., Manzar MD; Department of Nursing, College of Applied Medical Sciences, Majmaah University, Majmaah, Saudi Arabia., BaHammam AS; University Sleep Disorders Center, Department of Medicine, College of Medicine, King Saud University, Riyadh, Saudi Arabia.; Strategic Technologies Program of the National Plan for Sciences and Technology and Innovation in the Kingdom of Saudi Arabia., Jahrami H; College of Medicine and Medical Sciences, Arabian Gulf University, Manama, Kingdom of Bahrain.; Ministry of Health, Manama, Kingdom of Bahrain., Ramasubramanian C; Division of Community Psychiatry, M. S. Chellamuthu Trust and Research Foundation, Madurai, India., Karthikeyan R; Independent Researcher, Narayanapuram, Madurai, Tamil Nadu, India., Supasitthumrong T; Department of Psychiatry, Chulalongkorn University Faculty of Medicine, Bangkok, Thailand., Moscovitch A; Department of Psychiatry, Faculty of Medicine, University of Calgary, Calgary, Alberta, Canada., Trakht I; Department of Medicine, Columbia University, New York, NY, USA., Gupta R; Department of Psychiatry, All India Institute of Medical Sciences, Rishikesh, Uttarakhand, India., Narasimhan M; Department of Neuropsychiatry and Behavioral Science, Columbia, University of South Carolina, South Carolina, USA.; Department of Public Health and Welfare, Finnish Institute for Health and Welfare (THL), Helsinki, Finland., Partonen T; Department of Cell Systems and Anatomy, UT Health San Antonio, San Antonio, Texas USA., Reiter RJ; The Institute for Mental and Physical Health and Clinical Translation Strategy Research Centre, Deakin University School of Medicine, Geelong Victoria, Australia., Morris G; School of Public Health and Preventive Medicine, Monash University, Melbourne, Australia., Berk M; School of Public Health and Preventive Medicine, Monash University, Melbourne, Australia.; Department of Psychiatry, University of Melbourne, Parkville, Australia.; Orygen Youth Health Research Centre, Parkville, Australia.; Department of Psychiatry, University of Toronto, Canada., Kennedy SH; SAMRC Unit on Risk & Resilience in Mental Disorders, Department of Psychiatry & Neuroscience Institute, University of Cape Town, South Africa., Stein DJ; Neuroscience Education Institute, University of California San Diego, San Diego, CA, USA., Stahl SM; Departments of Psychiatry, Neuroscience, and Pharmacological Sciences, Mount Sinai School of Medicine, New York, NY, USA., Charney DS; Departments of Psychiatry, Neuroscience, and Pharmacological Sciences, Mount Sinai School of Medicine, New York, NY, USA., Seeman MV; SAMRC Unit on Risk & Resilience in Mental Disorders, Department of Psychiatry & Neuroscience Institute, University of Cape Town, South Africa. |
| المصدر: | Alpha psychiatry [Alpha Psychiatry] 2022 Jul 01; Vol. 23 (4), pp. 144-154. Date of Electronic Publication: 2022 Jul 01 (Print Publication: 2022). |
| نوع المنشور: | Journal Article; Review |
| اللغة: | English |
| بيانات الدورية: | Publisher: AVES Country of Publication: Turkey NLM ID: 9918284277106676 Publication Model: eCollection Cited Medium: Internet ISSN: 2757-8038 (Electronic) Linking ISSN: 27578038 NLM ISO Abbreviation: Alpha Psychiatry Subsets: PubMed not MEDLINE |
| أسماء مطبوعة: | Original Publication: Istanbul, Turkey : AVES, [2021]- |
| مستخلص: | Some research suggests that distress, secondary to isolation and fear following COVID-19 infection, can negatively affect the long-term more than the COVID-19 infection itself. This narrative review aims to provide a global view on the neuropsychiatric consequences of COVID-19 that can be ascribed to several factors, ranging from the direct effect of infection, to the body's responses against the infection, or to the psychological sequelae of social isolation, unemployment, and fear for one's health and livelihood. Current findings show that the more severe the respiratory infection, the more likely are central nervous system (CNS) complications regarding the infection itself. The immune reactions to the infection may result in symptoms similar to chronic fatigue as well as neurocognitive deficits, which last long after the infection is gone. An increase in symptoms of depression, anxiety, and trauma-related stress may also follow upon economic fears and isolation from friends and family. The consequences of the pandemic are not limited to adults; children learning remotely and away from classmates and routine activities may develop adjustment disorders, acute stress disorder, and a variety of manifestations of grief. A summary of case reports suggests that COVID-19-related stress, economic recession, and political unrest increase the risk of suicidal behaviors and acts of violence. However, it is unknown whether manifestations of mental disorders result from social causes or whether CNS complications may be responsible. Competing Interests: Conflict of Interest: The authors have read the journal's policy and have the following potential conflicts: Seithikurippu R. Pandi-Perumal, MSc., is a stockholder and the President and Chief Executive Officer of Somnogen Canada Inc., Toronto, Canada. He declares that he has no competing interests that might be perceived to influence the content of this article. This does not alter the authors’ adherence to all the journal policies. Dr Michael Berk has received Grant/Research Support from the NIH, Cooperative Research Centre, Simons Autism Foundation, Cancer Council of Victoria, Stanley Medical Research Foundation, Medical Benefits Fund, National Health and Medical Research Council, Medical Research Futures Fund, Beyond Blue, Rotary Health, A2 milk company, Meat and Livestock Board, Woolworths, Avant and the Harry Windsor Foundation, has been a speaker for Abbot, Astra Zeneca, Janssen and Janssen, Lundbeck and Merck and served as a consultant to Allergan, Astra Zeneca, Bioadvantex, Bionomics, Collaborative Medicinal Development, Eisai, Janssen and Janssen, Lundbeck Merck, Pfizer and Servier – all unrelated to this work. Ravi Gupta, MD, PhD, is a Member of the Advisory Board of Eisai Inc and Blackbeard Technology Private Limited, India. He declares that he has no competing interests that might be perceived to influence the content of this article. This does not alter the authors’ adherence to all the journal policies. Dan Stein, MD, PhD, received research grants and/or consultancy honoraria from Lundbeck and Sun. He declares that he has no competing interests that might be perceived to influence the content of this article. This does not alter the authors’ adherence to all the journal policies. Stephen M. Stahl, MD, PhD, Dsc (Hon.) is a consultant of the following companies: Acadia, Alkermes, Allergan, Arbor Pharmaceuticals, Axovant, Axsome, Celgene, Concert, ClearView, EMD Serono, Eisai Pharmaceuticals, Ferring, Impel NeuroPharma, Intra-Cellular Therapies, Ironshore Pharmaceuticals, Janssen, Lilly, Lundbeck, Merck, Otsuka, Pfizer, Sage Therapeutics, Servier, Shire, Sunovion, Takeda, Taliaz, Teva, Tonix, Tris Pharma, and Viforpharma. He is a board member of Genomind and on the speakers' bureau of Acadia, Lundbeck, Otsuka, Perrigo, Servier, Sunovion, Takeda, and Vertex. He received research and/or grant support from Acadia, Avanir, Braeburn Pharmaceuticals, Eli Lilly, Intra-Cellular Therapies, Ironshore, ISSWSH, Neurocrine, Otsuka, Shire, Sunovion, and TMS NeuroHealth Centers. He declares that he has no competing interests that might be perceived to influence the content of this article. This does not alter the authors’ adherence to all the journal policies. Dr. Charney reports, in addition, that he has a patent • US Patent No. 10 478 405 – Method for Treating Post-Traumatic Stress Disorder (issued November 19, 2019) issued; a patent • US Patent No. 10123737 – Systems and Methods for Treating a Psychiatric Disorder (issued November 13, 2018) licensed to Click Therapeutics, Inc.; a patent • US Patent No. 9592207 – Intranasal Administration of Ketamine to Treat Depression (issued March 14, 2017) licensed to Janssen Pharmaceuticals, Inc.; a patent • US Patent No. 9539220 – Methods for Treating Suicidal Ideation (issued January 10, 2017) licensed to Janssen Pharmaceuticals, Inc.; a patent • US Patent No. 8785500 – Intranasal Administration of Ketamine to Treat Depression (issued July 22, 2014) licensed to Janssen Pharmaceuticals, Inc., a patent • US Serial No. 16/189059 – and related foreign patent applications – Systems and Methods for Treating a Psychiatric Disorder, licensed to Click Therapeutics, Inc.; a patent • US Serial No. 17/041770 and related foreign patent applications – System and Methods for Processing Connectivity Values Between Sub-Processing Regions licensed to Click Therapeutics, Inc.; a patent • US CON Patent Appl No. 16/674381 and related foreign patent applications – Method for Treating Post Traumatic Stress Disorder (PTSD) pending; a patent • US Serial No. 14/889746 and a related European patent application – Treatment of Mood and Anxiety Disorders pending; and a patent • US Serial No. 16/844090 and US Serial No. 15/930140 – Intranasal Administration of Ketamine to Treat Depression. (Continuation patent applications in the same patent family as issued US Patents 8785500 and US 9539220 and US 9592207) licensed to Janssen Pharmaceuticals, Inc. All remaining authors declare that they have no proprietary, financial, professional, or any other personal interest of any nature or kind in any product or services and/or company that could be construed or considered a potential conflict of interest that might have influenced the views expressed in this manuscript. (© Copyright 2021 authors.) |
| References: | Lancet Child Adolesc Health. 2020 May;4(5):347-349. (PMID: 32224303) EClinicalMedicine. 2020 Apr 11;21:100348. (PMID: 32292900) Psychiatry Res. 2020 Aug;290:113115. (PMID: 32512352) Nat Sci Sleep. 2021 Jul 05;13:1037-1048. (PMID: 34262375) Neurosci Biobehav Rev. 2014 Sep;45:46-62. (PMID: 24858007) Med Sci Monit. 2020 Mar 05;26:e923549. (PMID: 32132521) Lancet Psychiatry. 2020 Apr;7(4):e21. (PMID: 32199510) Transl Psychiatry. 2020 Oct 6;10(1):339. (PMID: 33024072) Sleep Vigil. 2020;4(2):81-87. (PMID: 33015537) Acta Biomed. 2020 Oct 26;91(4):e2020131. (PMID: 33525217) J Psychiatr Res. 1995 Mar-Apr;29(2):141-52. (PMID: 7666381) Am J Crim Justice. 2020;45(4):647-667. (PMID: 32837171) Int J Infect Dis. 2020 Jul;96:192-195. (PMID: 32389845) Psychiatry Clin Neurosci. 2020 Apr;74(4):281-282. (PMID: 32034840) J Sleep Res. 2020 Aug;29(4):e13074. (PMID: 32410272) BMJ. 2021 Mar 10;372:n614. (PMID: 33692087) J Med Virol. 2005 Feb;75(2):185-94. (PMID: 15602737) Pathog Glob Health. 2021 Sep;115(6):357-364. (PMID: 34057046) JAMA Pediatr. 2021 Nov 1;175(11):1142-1150. (PMID: 34369987) J Clin Sleep Med. 2020 Jul 15;16(7):1215. (PMID: 32323647) J Infect. 2020 Aug;81(2):e16-e25. (PMID: 32335169) J Psychiatr Res. 2020 Nov;130:177-179. (PMID: 32823051) Front Psychiatry. 2022 Feb 03;12:809040. (PMID: 35185640) Lancet. 2021 May 1;397(10285):1603-1605. (PMID: 33865497) BMC Infect Dis. 2021 Jul 27;21(1):710. (PMID: 34315427) J Clin Sleep Med. 2021 Feb 1;17(2):299-313. (PMID: 33108269) Lancet Psychiatry. 2020 Jun;7(6):468-471. (PMID: 32330430) Braz J Psychiatry. 2020;42(3):232-235. (PMID: 32267343) Mol Psychiatry. 2022 Jan;27(1):34-37. (PMID: 34140635) Psychiatry Res. 2020 Aug;290:113145. (PMID: 32544650) Nature. 2020 Aug;584(7820):170. (PMID: 32782377) Psychiatry. 2007 Winter;70(4):283-315; discussion 316-69. (PMID: 18181708) Arch Med Res. 2020 Jul;51(5):384-387. (PMID: 32402576) Med Sci Monit. 2020 Mar 20;26:e923921. (PMID: 32194290) World Psychiatry. 2020 Jun;19(2):129-130. (PMID: 32394569) Saudi Med J. 2021 Apr;42(4):384-390. (PMID: 33795493) AIDS Behav. 2020 Jul;24(7):2003-2006. (PMID: 32266502) Int J Soc Psychiatry. 2020 Feb;66(1):34-40. (PMID: 31564187) Gen Psychiatr. 2020 Jun 14;33(3):e100259. (PMID: 32596640) Eur Psychiatry. 2020 Apr 01;63(1):e32. (PMID: 32234102) Brain Behav Immun. 2020 Jul;87:34-39. (PMID: 32298803) Sleep Vigil. 2021;5(1):1-2. (PMID: 34027301) Bipolar Disord. 2021 Dec;23(8):847-849. (PMID: 34477297) Lancet Psychiatry. 2021 Feb;8(2):130-140. (PMID: 33181098) Lancet. 2020 Apr 11;395(10231):1194. (PMID: 32246915) BMC Psychiatry. 2020 Jul 17;20(1):379. (PMID: 32680478) Psychiatry Res. 2020 Sep;291:113254. (PMID: 32603930) Lancet Psychiatry. 2020 Oct;7(10):875-882. (PMID: 32593341) Brain Behav Immun. 2022 Mar;101:93-135. (PMID: 34973396) Int J Environ Res Public Health. 2020 Jul 02;17(13):. (PMID: 32630821) Gen Hosp Psychiatry. 2021 Nov-Dec;73:84-100. (PMID: 34717240) BJPsych Open. 2020 Sep 10;6(5):e109. (PMID: 32907692) BMJ Case Rep. 2020 Jun 14;13(6):. (PMID: 32540882) Psychiatry Res. 2021 Jul;301:113998. (PMID: 34022657) Qatar Med J. 2021 Nov 30;2021(3):65. (PMID: 34888201) Child Adolesc Ment Health. 2020 Sep;25(3):167-168. (PMID: 32654361) Lancet. 2020 Apr 18;395(10232):1250-1251. (PMID: 32224298) Sci Total Environ. 2020 Aug 15;730:139086. (PMID: 32375105) Lancet Psychiatry. 2020 Jul;7(7):611-627. (PMID: 32437679) Sleep Vigil. 2021;5(2):221-226. (PMID: 34104854) Brain Behav Immun. 2020 Oct;89:594-600. (PMID: 32738287) BMJ. 2020 Mar 26;368:m1091. (PMID: 32217556) J Anxiety Disord. 2020 Aug;74:102268. (PMID: 32650221) BJPsych Open. 2020 Aug 17;6(5):e90. (PMID: 32799958) J Affect Disord. 2020 Oct 1;275:112-118. (PMID: 32658812) Nat Hum Behav. 2020 May;4(5):439. (PMID: 32221513) Neuropsychopharmacology. 1999 Apr;20(4):370-9. (PMID: 10088138) Disaster Med Public Health Prep. 2013 Feb;7(1):105-10. (PMID: 24618142) Medicina (Kaunas). 2021 Dec 23;58(1):. (PMID: 35056325) JAMA. 2020 Jun 2;323(21):2133-2134. (PMID: 32259193) Sleep Vigil. 2020;4(2):51-53. (PMID: 33289005) J Affect Disord. 2020 Oct 1;275:69-77. (PMID: 32658826) Psychiatry Res. 2020 May;287:112934. (PMID: 32229390) Can J Anaesth. 2020;67(10):1471-1474. (PMID: 32425331) Psychiatry Res. 2020 Aug;290:113134. (PMID: 32505030) Psychiatry Res. 2020 Jun;288:112954. (PMID: 32325383) J Health Psychol. 2021 Jan;26(1):115-125. (PMID: 32830577) Int J Environ Res Public Health. 2020 Mar 06;17(5):. (PMID: 32155789) Lancet Glob Health. 2020 May;8(5):e641-e642. (PMID: 32199072) Mol Neurobiol. 2019 Jan;56(1):141-156. (PMID: 29681025) J Sleep Res. 2022 Feb;31(1):e13432. (PMID: 34245055) J Clin Sleep Med. 2020 Aug 15;16(8):1401-1402. (PMID: 32400388) JAMA Netw Open. 2020 Mar 2;3(3):e203976. (PMID: 32202646) Int J Ment Health Nurs. 2020 Jun;29(3):315-318. (PMID: 32277578) PLoS Med. 2020 Jun 16;17(6):e1003144. (PMID: 32544156) Asian J Psychiatr. 2020 Dec;54:102350. (PMID: 33271682) Prog Neuropsychopharmacol Biol Psychiatry. 2021 Jul 13;109:110207. (PMID: 33338558) J Affect Disord. 2020 Oct 1;275:48-57. (PMID: 32658823) Front Public Health. 2021 Mar 05;9:603273. (PMID: 33748059) World Psychiatry. 2021 Feb;20(1):54-55. (PMID: 33131217) Asian J Psychiatr. 2020 Dec;54:102365. (PMID: 33271687) N Engl J Med. 2020 May 14;382(20):e60. (PMID: 32343504) JAMA Neurol. 2020 Jun 1;77(6):683-690. (PMID: 32275288) BMJ. 2020 Jan 16;368:l6890. (PMID: 31948937) Chin Med J (Engl). 2020 May 5;133(9):1025-1031. (PMID: 32044814) J Child Adolesc Psychiatr Nurs. 2021 May;34(2):139-146. (PMID: 33811706) |
| فهرسة مساهمة: | Keywords: COVID-19; SARS-CoV-2; mental illness; psychiatry; sleep |
| تواريخ الأحداث: | Date Created: 20221125 Latest Revision: 20221126 |
| رمز التحديث: | 20221213 |
| مُعرف محوري في PubMed: | PMC9590656 |
| DOI: | 10.5152/alphapsychiatry.2022.21783 |
| PMID: | 36425743 |
| قاعدة البيانات: | MEDLINE |
| تدمد: | 2757-8038 |
|---|---|
| DOI: | 10.5152/alphapsychiatry.2022.21783 |